Published Patent Application 2004/0192676 (disclosing a small molecule asserted to be a melanocortin receptor agonist in a pharmaceutical composition including sildenafil)
Part D, conversely, is for drugs the patient administers(filled at pharmacy)
Therefore, drugs that target these mechanisms, such as GLP-1 RAs, might have beneficial effects in both diseases. Daniel Truong, MD In some studies, the prevalence of Parkinsons disease was lower among patients with diabetes who were treated with glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 inhibitors, which increase GLP-1 levels, than among patients who received other diabetes medications, Truong said
McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, et al
According to the Wegovy SmPC, clinically relevant interactions with most oral medicines are not expected despite this effect
Scientists are still figuring that out, but early indications are that the cause is not the drugs themselves but some of the lifestyle changes the drugs can lead to